Clinical Trial Update: High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 results are reported for high-dose rituximab as initial therapy for indolent non-Hodgkin lymphoma. The trial has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: B-cell Lymphoma, Indolent B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-09